相关实验视频

Updated: May 24, 2025

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

利用机器学习和人工智能驱动的分析来识别新型药物标,并预测NSCLC中化疗的疗效

Shaojia Qin¹, Biyu Deng¹, Dan Mo¹

¹Department of Pulmonary and Critical Care Medicine, Laibin People's Hospital, Laibin, China.

Frontiers in pharmacology

|March 6, 2025

概括

线粒体衍生RNAs (mtRNAs) 与AI结合预测非小细胞肺癌 (NSCLC) 患者的结果. 这种方法改善了无进展和整体生存的风险分层,有助于精确瘤学.

科学领域:

生物标志物和诊断仪器
计算生物学和生物信息学
瘤学和癌症研究.

背景情况:

非小细胞肺癌 (NSCLC) 呈现出显著的异质性,影响化疗反应.
线粒体衍生RNAs (mtRNAs) 显示为癌症的新生物标志物具有前途.
在NSCLC化疗结果中mtRNAs的预测作用需要进一步研究.

研究的目的:

探索mtRNA比率作为NSCLC中的生物标志物的实用性.
为了评估AI驱动的变量 (BiomedGPT得分) 进行NSCLC预测.
评估临床数据,mtRNAs和AI在NSCLC中的联合预测能力.

主要方法:

在NSCLC患者中分析mtRNA比率 (mt_tRNA-Tyr-GTA_5_end到mt_tRNA-Phe-GAA).
从胸部CT图像中导出一个人工智能驱动的BiomedGPT变量.
将临床因素,生物医学GPT得分和mtRNA比率整合到预测模型中.

主要成果:

单个临床因素的预测价值有限,但随机森林模型有所改善.
整合BiomedGPT得分和mtRNA比率显著提高了预测性能.
一个综合模型结合了临床数据,AI和mtRNAs,创建了一个风险得分,区分患者生存结果.

结论:

将mtRNA生物标志物与人工智能方法相结合,可以改进NSCLC的治疗决策.
整合各种数据源,包括人工智能和分子生物标志物,对于精确瘤学至关重要.
这种综合方法为改善NSCLC患者管理和预测结果提供了一个有希望的策略.

关键词:

生物医学GPTPT 人工智能是一种人工智能.生物标志物发现发现化疗反应的化学疗法反应.机器学习是机器学习.线粒体衍生RNAs (mtRNAs) 是一种非小细胞肺癌 (NSCLC) 是一种非小细胞肺癌.

更多相关视频

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

Automation of the Micronucleus Assay Using Imaging Flow Cytometry and Artificial Intelligence

Automation of the Micronucleus Assay Using Imaging Flow Cytometry and Artificial Intelligence

Published on: January 27, 2023

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...